Quotes 5-day view Delayed Nyse
01/11/2021
01/12/2021
01/13/2021
01/14/2021
01/15/2021
Date
77.19(c)
77.99(c)
84.18(c)
86.71(c)
86.34(c)
Last
197 566
233 788
737 100
1 116 809
295 657
Volume
-1.33% +1.04% +7.94% +3.01% -0.43% Change
Sales 2020
219 M - -
Net income 2020
-124 M - -
Net cash position 2020
201 M - -
P/E ratio 2020
-31,4x
Yield 2020
-
Sales 2021
290 M - -
Net income 2021
-57,6 M - -
Net cash position 2021
216 M - -
P/E ratio 2021
-71,5x
Yield 2021
-
Capitalization
3 880 M 3 880 M -
EV / Sales 2020
16,8x
EV / Sales 2021
12,6x
Nbr of Employees
600
Free-Float
96,8%
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the...
Notations Surperformance© of Glaukos Corporation
Trading Rating : Investor Rating :
All news about GLAUKOS CORPORATION
News in other languages on GLAUKOS CORPORATION
Analyst Recommendations on GLAUKOS CORPORATION
Chart GLAUKOS CORPORATION
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends GLAUKOS CORPORATION
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
12
Average target price
63,80 $
Last Close Price
86,34 $
Spread / Highest target
-7,34%
Spread / Average Target
-26,1%
Spread / Lowest Target
-44,4%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
